Document is current
Any future updates will be listed below
-
Authors
Pellerin, David
Iruzubieta, Pablo
Xu, Isaac R. L.
Danzi, Matt C.
Cortese, Andrea
Synofzik, Matthis
Houlden, Henry
Zuchner, Stephan
Brais, Bernard
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/T001712/1)
Fondazione Cariplo (2019-1836)
Inherited Neuropathy Consortium
Fondazione Regionale per la Ricerca Biomedica (1751723)
PRIN (F53D23002330006 - 20229MMHXP)
Muscular Dystrophy UK
AFM Telethon
European Research Council
Else Kröner-Fresenius-Stiftung
European’s Union Horizon 2020 research and innovation program (779257)
Deutsche Forschungsgemeinschaft (441409627)
European Joint Programme on Rare Diseases (825575, 825575, 825575, 825575)
Wellcome Trust
UCLH/UCL Biomedical Research Centre
National Institutes of Neurological Disorders and Stroke (2R01NS072248-11A1)
Fondation Groupe Monaco
Canadian Institutes of Health Research (189963)
- License Information
-
More Information
Article History
Accepted: 4 December 2024
First Online: 16 January 2025
Declarations
:
: Not applicable.
: DP reports no disclosures. PI reports no disclosures. IRLX reports no disclosures. MCD reports no disclosures. AC reports no disclosures. MS has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly, and Solaxa, all unrelated to the present manuscript. HH reports no disclosures. SZ reports no disclosures. BB reports no disclosures.
